{"id":"W3202236569","doi":"10.1158/1078-0432.ccr-21-1181","title":"Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Università degli Studi di Milano; Bristol-Myers Squibb","keywords":"Nivolumab; Maximum tolerated dose; Clinical trial; Solid tumor; Immunotherapy; Phases of clinical research; Cytotoxic T cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00101017,0.001375032,0.001433955,0.0002667237,0.0002889272,0.0007238994,0.0005662215,0.0008336329,0.002611195],"category_scores_gemma":[0.0004129784,0.0004879413,0.0009551448,0.000305681,0.000655057,0.0005277565,0.0002199834,0.001989847,0.0008491772],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006629005,"about_ca_system_score_gemma":0.0009755424,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006010876,"about_ca_topic_score_gemma":0.001900472,"domain_scores_codex":[0.9997793,0.0001044232,0.00001453303,0.0000396356,0.00002163267,0.00004046937],"domain_scores_gemma":[0.999707,0.00003720727,0.00007223295,0.00002222455,0.000018055,0.0001431922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7404884,0.04019801,0.006649383,0.001324508,0.001203346,0.0002649024,0.0002176136,0.002360571,0.09473328,0.0002455323,0.003715488,0.1085991],"study_design_scores_gemma":[0.5006267,0.4746628,0.01356648,0.00004603349,0.0004854199,0.0002908219,0.00004615156,0.001158622,0.006286664,0.000115341,0.00269078,0.00002421015],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929746,0.003093857,0.0002754501,0.0002484839,0.000136002,0.001085303,0.0004182389,0.00007299968,0.00169508],"genre_scores_gemma":[0.9924634,0.00198581,0.0008082107,0.000446771,0.0001882825,0.0008019368,0.001131231,0.00001895374,0.002155543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002611195,"threshold_uncertainty_score":0.008735299,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1419866974866878,"score_gpt":0.559179952943152,"score_spread":0.4171932554564642,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}